Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis reportPriya S. Kishnani, Yin‐Hsiu Chien, James Davison et al.|Genetics in Medicine|2022Cited by 53
OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfaDavid Kronn, On behalf of the Mini-COMET investigators, James Davison et al.|Genetics in Medicine|2022Cited by 10